Quantifying Disease Progression in LBSL

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-11

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Leukoencephalopathy with brain stem involvement and lactate elevation (LBSL) is a genetic disorder caused by biallelic mutations in the DARS2 gene that encodes mitochondrial aspartyl tRNA synthase.(1, 2) It is characterized by typical abnormalities on MRI of the brain and spinal cord.(3) Clinically, the disorder is heterogeneous and can present in the neonatal period, later in childhood or even in adults.(3) In general it can be stated that the earlier presentations are characterized by rapid progression leading to severe disability and death. Presentation at a later age is typically characterized by a more benign disease course, although considerable disability is common. Clinically, the disease presents as a slowly progressive myelopathy with mainly involvement of the corticospinal tracts and the dorsal columns. Although the natural history has been studied in large cohorts, the rate of progression has not been systematically studied with clinimetric outcome scales or potential surrogate outcomes for spinal cord disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31

NCT02859428

Hereditary Spastic Paraplegia

TERMINATED

STOP-HSP.Net: a Registry for Hereditary Spastic Paraplegia as an Integration Tool for Future Therapeutic Strategies

NCT06572046

Hereditary Spastic Paraplegia

RECRUITING

Renal HYPODYSPLASIA : Genetic and Familial Assessment

NCT00925379

Renal HYPODYSPLASIA, Nonsyndromic, 1

COMPLETED

Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform.

NCT00154960

Spinal Muscular Atrophy Neonatal Hyperbilirubinemia Colon Cancer

UNKNOWN

Lymphangioleiomyomatosis, a Study on Cathepsin K

NCT05323370

Lymphangioleiomyomatosis Tuberous Sclerosis Complex

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

LBSL Leukoencephalopathies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 16 years
* Definite diagnosis of LBSL confirmed by DARS2 mutation analysis.
* Able to understand Dutch or English and provide informed consent.
* No contra-indications for MRI of brain and spinal cord.

Subjects eligible to participate as healthy controls must meet all of the following criteria:

* Willing to visit the hospital
* 16 years or older
* Provision of written informed consent to participate in the study obtained from the participant

For the MRI controls:

\- No contra-indications for MRI of the brain and spinal cord

A potential subject (patient or healthy control) who meets any of the following criteria will be excluded from participation in this study:

* Unable to visit the hospital for the follow-up visits
* Co-existing neurological disease that can cause pyramidal tract signs making interpretation of acquired data difficult (for instance, multiple sclerosis, stroke, etc)

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes